ROBERT KRANCE to Recurrence
This is a "connection" page, showing publications ROBERT KRANCE has written about Recurrence.
Connection Strength
0.621
-
Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695.
Score: 0.118
-
Allogeneic hematopoietic cell transplant following crizotinib monotherapy for relapsed/refractory anaplastic large cell lymphoma. Pediatr Transplant. 2018 08; 22(5):e13210.
Score: 0.107
-
Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72.
Score: 0.086
-
Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52.
Score: 0.056
-
Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2024 02; 30(2):217-227.
Score: 0.039
-
Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711.
Score: 0.035
-
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
Score: 0.033
-
Gene marking after bone marrow transplantation. Eur J Cancer. 1994; 30A(8):1171-6.
Score: 0.020
-
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
Score: 0.019
-
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83.
Score: 0.017
-
A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study. Cancer. 1991 Feb 01; 67(3):550-6.
Score: 0.016
-
Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood. 2011 Mar 03; 117(9):2728-34.
Score: 0.016
-
Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. Cytotherapy. 2002; 4(3):253-8.
Score: 0.009
-
Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75.
Score: 0.008
-
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
Score: 0.008
-
Use of gene marking in bone marrow transplantation. Cancer Detect Prev. 1996; 20(2):108-13.
Score: 0.006
-
Gene marking and autologous bone marrow transplantation. Ann N Y Acad Sci. 1994 May 31; 716:204-14; discussion 214-5, 225-7.
Score: 0.005
-
Gene transfer and bone marrow transplantation. Cold Spring Harb Symp Quant Biol. 1994; 59:691-7.
Score: 0.005
-
Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993 Jul 29; 329(5):314-9.
Score: 0.005
-
Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993 Jan 09; 341(8837):85-6.
Score: 0.005
-
An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. Blood. 1992 May 15; 79(10):2694-700.
Score: 0.004
-
Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol. 1987 Nov; 5(11):1822-6.
Score: 0.003